KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer

• Published in: Balkan medical journal 2016-07, Vol.33 (4), p.407-410
• Main Authors: Kodaz, Hilmi, Taştekin, Ebru, Erdoğan, Bülent, Hacıbekiroğlu, İlhan, Tozkır, Hilmi, Gürkan, Hakan, Türkmen, Esma, Demirkan, Bora, Uzunoğlu, Sernaz, Çiçin, İrfan
• Format: Article
• Language: English
• Subjects: extrapulmonary small cell carcinoma; KRAS mutation; Original; Small cell lung cancer; Tıp
• ISSN: 2146-3123; 2146-3131
• DOI: 10.5152/balkanmedj.2016.150610

Lung cancer is one of the most lethal cancers. It is mainly classified into 2 groups: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Extrapulmonary small cell carcinomas (EPSCC) are very rare. The Ras oncogene controls most of the cellular functions in the cell. Overall, 21.6% of human cancers contain a Kirsten Ras (KRAS) mutation. SCLC and EPSCC have several similar features but their clinical course is different. We investigated the KRAS mutation status in SCLC and EPSCC. Mutation research. Thirty-seven SCLC and 15 EPSCC patients were included in the study. The pathological diagnoses were confirmed by a second pathologist. KRAS analysis was performed in our medical genetic department. DNA isolation was performed with primary tumor tissue using the QIAamp DNA FFPE Tissue kit (Qiagen; Hilden, Germany) in all patients. The therascreen KRAS Pyro Kit 24 V1 (Qiagen; Hilden, Germany) was used for KRAS analyses. Thirty-four (91.9%) of the SCLC patients were male, while 11 (73.3%) of the EPSCC l patients were female. SCLC was more common in males, and EPSCC in females (p=0.001). A KRAS mutation was found in 6 (16.2%) if SCLC patients. The most common mutation was Q61R (CAA>CGA). Among the 15 EPSCC patients, 2 had a KRAS mutation (13.3%). When KRAS mutant and wild type patients were compared in the SCLC group, no difference was found for overall survival (p=0.6). In previous studies, the incidence of KRAS mutation in SCLC was 1-3%; however, it was 16.2% in our study. Therefore, there may be ethnic and geographical differences in the KRAS mutations of SCLC. As a result, KRAS mutation should not be excluded in SCLC.